Trial · NCT01876212
Results by group46
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 46
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Immune Response Rate | Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) | 0.29 | 95% Confidence Interval 0.04 to 0.71 | proportion of participants | |
| Immune Response Rate | Vaccine + Dasatinib (Cycle 1, D1) | 0.67 | 95% Confidence Interval 0.22 to 0.96 | proportion of participants | |
| Best Clinical Response | Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) | Partial Response | 0 | Participants | |
| Best Clinical Response | Vaccine + Dasatinib (Cycle 1, D1) | Partial Response | 4 | Participants | |
| Best Clinical Response | Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) | Progressed Disease | 4 | Participants | |
| Best Clinical Response | Vaccine + Dasatinib (Cycle 1, D1) | Progressed Disease | 2 | Participants | |
| Best Clinical Response | Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) | Stable Disease | 3 | Participants | |
| Best Clinical Response | Vaccine + Dasatinib (Cycle 1, D1) | Stable Disease | 0 | Participants | |
| Objective Response Rate (ORR) | Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) | 0 | 95% Confidence Interval 0 to 0.4096 | proportion of participants | |
| Objective Response Rate (ORR) | Vaccine + Dasatinib (Cycle 1, D1) | 0.6667 | 95% Confidence Interval 0.2228 to 0.9567 | proportion of participants | |
| Worst Grade of Any Toxicity | Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) | Grade 2 Toxicity | 1 | Participants | |
| Worst Grade of Any Toxicity | Vaccine + Dasatinib (Cycle 1, D1) | Grade 2 Toxicity | 2 | Participants | |
| Worst Grade of Any Toxicity | Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) | Grade 3 Toxicity | 6 | Participants | |
| Worst Grade of Any Toxicity | Vaccine + Dasatinib (Cycle 1, D1) | Grade 3 Toxicity | 3 | Participants | |
| Worst Grade of Any Toxicity | Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) | Grade 4 Toxicity | 0 | Participants | |
| Worst Grade of Any Toxicity | Vaccine + Dasatinib (Cycle 1, D1) | Grade 4 Toxicity | 1 | Participants | |
| Worst Grade of Any Toxicity | Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) | Grade 5 Toxicity | 1 | Participants | |
| Worst Grade of Any Toxicity | Vaccine + Dasatinib (Cycle 1, D1) | Grade 5 Toxicity | 0 | Participants | |
| Worst Grade of Any Toxicity | Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) | No >Grade 2 Toxicity | 1 | Participants | |
| Worst Grade of Any Toxicity | Vaccine + Dasatinib (Cycle 1, D1) | No >Grade 2 Toxicity | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01876212/results